TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer: a Pilot Randomized Controlled Trial
Brief Summary: Epidemiologic data consistently indicate that colorectal cancer survivors can improve their quality-of-life and prognosis by engaging in physical activity. This study aims to build on this epidemiologic work and translate the findings to inform and change patient behavior. The specific aims are to: (1) Develop a mobile technology physical activity intervention among colorectal cancer patients who have completed therapy. (2) Conduct a 3-month pilot randomized controlled trial utilizing mobile technology to increase physical activity among 40 men and women who have completed standard cytotoxic chemotherapy for primary stage I-III colorectal cancer at the UCSF Helen Diller Family Comprehensive Cancer Center. Participants in the intervention arm will receive a Fitbit® for self-monitoring, interactive text messages, and educational print materials; participants in the control arm will receive educational print materials at baseline and will be given a Fitbit® after completion of the 3-mo. follow-up assessment.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Digital Health Physical Activity Intervention Group | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Digital Health Physical Activity Intervention Group; Assigned to Arm(s): Intervention
B: Arm Label: High intensity; Type: EXPERIMENTAL; Interventions: Behavioral: high intensity exercise | Arm Label: Low/Medium intensity; Type: EXPERIMENTAL; Interventions: Behavioral: low/medium intensity exercise | Arm Label: High Intensity with BM; Type: EXPERIMENTAL; Interventions: Behavioral: high intensity exercise, Behavioral: Behavioral medicine strategies | Arm Label: Low/Medium intensity with BM; Type: EXPERIMENTAL; Interventions: Behavioral: low/medium intensity exercise, Behavioral: Behavioral medicine strategies | Intervention Type: BEHAVIORAL; Name: high intensity exercise; Assigned to Arm(s): High Intensity with BM, High intensity | Intervention Type: BEHAVIORAL; Name: low/medium intensity exercise; Assigned to Arm(s): Low/Medium intensity, Low/Medium intensity with BM | Intervention Type: BEHAVIORAL; Name: Behavioral medicine strategies; Assigned to Arm(s): High Intensity with BM, Low/Medium intensity with BM
C: Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral dietary and exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary and exercise intervention; Assigned to Arm(s): Lifestyle counseling
D: Arm Label: Hatha yoga; Type: EXPERIMENTAL; Interventions: Behavioral: Hatha yoga | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Hatha yoga; Assigned to Arm(s): Hatha yoga

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Tranexamic Acid Use in Transfusion Rate in Patients With Complex Kidney Stone Undergoing Percutaneous Nephrolithotomy: Randomised, Double-blind, Placebo Controlled Trial
Brief Summary: This study is a double blinded randomized controlled trial evaluating the impact of tranexamic acid use on the transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy.


Options:
A: Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PCNL | Arm Label: mini-PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: mini-PCNL | Arm Label: RIRS Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIRS | Intervention Type: PROCEDURE; Name: PCNL; Assigned to Arm(s): PCNL Group | Intervention Type: PROCEDURE; Name: mini-PCNL; Assigned to Arm(s): mini-PCNL Group | Intervention Type: PROCEDURE; Name: RIRS; Assigned to Arm(s): RIRS Group
C: Arm Label: RIRS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Retrograde intrarenal surgery | Arm Label: PCNL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous nephrolithotomy | Intervention Type: PROCEDURE; Name: Percutaneous nephrolithotomy; Assigned to Arm(s): PCNL | Intervention Type: PROCEDURE; Name: Retrograde intrarenal surgery; Assigned to Arm(s): RIRS
D: Arm Label: Tranexamic Acid Group; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid Group | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Phase III, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Currently ESA Users
Brief Summary: Daprodustat is a drug that is currently being developed as a treatment for renal anemia . This study is to evaluate the efficacy and safety of daprodustat following a switch from erythropoiesis-stimulating agent (ESA) in Japanese HD subjects with renal anemia who are currently treated with ESA. The primary objective is to demonstrate non-inferiority of daprodustat to darbepoetin alfa. This study is a 52-week, Phase III, double-blind, active-controlled, parallel-group, multi-center study. The total duration of the study will be approximately 58 weeks including screening and follow-up.


Options:
A: Arm Label: AKB-6548; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AKB-6548; Assigned to Arm(s): AKB-6548 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 0.5 mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 2 mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 5 mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: rhEPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: rhEPO | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): 0.5 mg GSK1278863, 2 mg GSK1278863, 5 mg GSK1278863 | Intervention Type: DRUG; Name: rhEPO; Assigned to Arm(s): rhEPO
C: Arm Label: Desidustat oral tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desidustat Oral Tablet | Arm Label: Epoetin Injection; Type: EXPERIMENTAL; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Desidustat Oral Tablet; Assigned to Arm(s): Desidustat oral tablet | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Injection
D: Arm Label: Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat small, Drug: Daprodustat large, Drug: Darbepoetin alfa placebo | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daprodustat small placebo, Drug: Daprodustat large placebo, Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Daprodustat small; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: Daprodustat small placebo; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Daprodustat large; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: Daprodustat large placebo; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa placebo; Assigned to Arm(s): Daprodustat

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Full-mouth Periodontal Debridement Associated With Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial
Brief Summary: The aim of this study is to assess the clinical outcomes of full-mouth ultrasonic debridement combined with clarithromycin or amoxicillin + metronidazole association for the treatment of generalized aggressive periodontitis (GAgP).


Options:
A: Arm Label: Scaling and root planing alone; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Scaling and root planing | Arm Label: SRP + Metronidazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole | Arm Label: SRP + MET + Amoxicillin + Doxycycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin, Drug: Doxycycline | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): Scaling and root planing alone | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): SRP + Metronidazole | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): SRP + MET + Amoxicillin + Doxycycline | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): SRP + MET + Amoxicillin + Doxycycline
B: Arm Label: Amoxicillin and Metronidazole; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Full-mouth ultrasonic debridement, Drug: Amoxicillin, Drug: Metronidazole | Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Procedure: Full-mouth ultrasonic debridement, Drug: Clarithromycin | Intervention Type: PROCEDURE; Name: Full-mouth ultrasonic debridement; Assigned to Arm(s): Amoxicillin and Metronidazole, Clarithromycin | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Clarithromycin | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Amoxicillin and Metronidazole | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Amoxicillin and Metronidazole
C: Arm Label: scaling and root planing; Type: PLACEBO_COMPARATOR; Interventions: Other: scaling and root planing | Arm Label: scaling and systemic moxifloxacin; Type: EXPERIMENTAL; Interventions: Other: scaling and systemic moxifloxacin | Intervention Type: OTHER; Name: scaling and systemic moxifloxacin; Assigned to Arm(s): scaling and systemic moxifloxacin | Intervention Type: OTHER; Name: scaling and root planing; Assigned to Arm(s): scaling and root planing
D: Arm Label: Moxifloxacin; Type: EXPERIMENTAL; Interventions: Drug: moxifloxacin | Arm Label: Ciprofloxacin plus metronidazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciprofloxacin plus metronidazole | Intervention Type: DRUG; Name: moxifloxacin; Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Ciprofloxacin plus metronidazole; Assigned to Arm(s): Ciprofloxacin plus metronidazole

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Time-restricted Feeding on Physiological Function in Middle-aged and Older Adults
Brief Summary: The purpose of this study is to assess the safety and efficacy of time-restricted feeding (eating within an 8-hour window) for improving physiological function (vascular, motor, cognitive and metabolic function) in healthy middle-aged and older adults.


Options:
A: Arm Label: Calorie restriction (MACR); Type: EXPERIMENTAL; Interventions: Behavioral: Calorie restriction (MACR) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Calorie restriction (MACR); Assigned to Arm(s): Calorie restriction (MACR)
B: Arm Label: ketogenic diet and transient fasting; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calorie-restricted ketogenic diet and transient fasting | Arm Label: standard nutrition; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: calorie-restricted ketogenic diet and transient fasting; Assigned to Arm(s): ketogenic diet and transient fasting | Intervention Type: DIETARY_SUPPLEMENT; Name: standard nutrition; Assigned to Arm(s): standard nutrition
C: Arm Label: TRF; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restricted Feeding | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Time Restricted Feeding; Assigned to Arm(s): TRF | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: Normal Feeding; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Time Restricted Feeding; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restricted Feeding | Intervention Type: BEHAVIORAL; Name: Time Restricted Feeding; Assigned to Arm(s): Time Restricted Feeding

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
Brief Summary: This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).


Options:
A: Arm Label: ABT-199 after ibrutinib therapy; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax | Arm Label: ABT-199 after idelalisib therapy; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax | Arm Label: ABT-199 after ibrutinib therapy: Expansion Cohort; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax | Arm Label: ABT-199 after idelalisib therapy: Expansion Cohort; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): ABT-199 after ibrutinib therapy, ABT-199 after ibrutinib therapy: Expansion Cohort, ABT-199 after idelalisib therapy, ABT-199 after idelalisib therapy: Expansion Cohort
B: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide
C: Arm Label: Obinutuzumab; Type: EXPERIMENTAL; Interventions: Drug: obinutuzumab (RO5072759) | Arm Label: Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: rituximab | Intervention Type: DRUG; Name: obinutuzumab (RO5072759); Assigned to Arm(s): Obinutuzumab | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): Rituximab
D: Arm Label: Acalabrutinib (ACP-196); Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib (ACP-196) | Arm Label: Rituximab Plus Idelalisib or Bendamustine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab, Drug: Idelalisib, Drug: Bendamustine | Intervention Type: DRUG; Name: Acalabrutinib (ACP-196); Assigned to Arm(s): Acalabrutinib (ACP-196) | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab Plus Idelalisib or Bendamustine | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Rituximab Plus Idelalisib or Bendamustine | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Rituximab Plus Idelalisib or Bendamustine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of a Social Media Intervention for Exercise Motivation and Cardiac Rehabilitation Adherence
Brief Summary: While cardiac rehabilitation (CR) has been shown to be effective at improving cardiovascular disease (CVD), participation is generally poor. The current feasibility study, will evaluate the impact of a social media intervention on motivation for exercise and adherence to CR sessions. Participants will be randomly assigned to a Facebook™ group or an enhanced education comparison group. The intervention will include access to a private Facebook™ group in which participants will receive weekly educational posts, weekly provider support and have the opportunity to communicate with other cardiac rehabilitation patients. Patients in the comparison group will be given the same educational materials, but these will be supplied in email. Participants will be asked to fill out a pre-post motivational questionnaire and the total number of sessions attended at the end of 3 months will be tallied. This study is grounded in Self-Determination Theory (SDT) and utilizes the Behavioral Regulation in Exercise Questionnaire (BREQ-2), which is based on the SDT.


Options:
A: Arm Label: Facebook group; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook | Arm Label: Comparison group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facebook | Intervention Type: BEHAVIORAL; Name: Facebook; Assigned to Arm(s): Comparison group, Facebook group
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healing Circles; Type: EXPERIMENTAL; Interventions: Behavioral: Healing Circles | Intervention Type: BEHAVIORAL; Name: Healing Circles; Assigned to Arm(s): Healing Circles
C: Arm Label: Cardiac Rehabilitation Peer Mentorship; Type: EXPERIMENTAL; Interventions: Behavioral: Cardiac Rehabilitation Peer Mentorship | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation Peer Mentorship; Assigned to Arm(s): Cardiac Rehabilitation Peer Mentorship
D: Arm Label: Distress management; Type: EXPERIMENTAL; Interventions: Behavioral: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives; Assigned to Arm(s): Distress management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ultrashort Cognitive Behavioral Intervention for Tokophobia- A Prospective Randomized Single Blinded Controlled Trial
Brief Summary: Women in their 3rd trimester, represent a unique segment of the tokophobic population. In these cases help is needed within a very short and limited period of time. To date, no specific treatment targets this population in order to ameliorate the anxiety and to provide these women and their newborns with better obstetric and psychiatric outcomes. The present study investigates an accessible individual two session intervention conducted by midwives skilled in CBT (cognitive behavioral therapy) . This intervention is designed to enable stronger emotional regulation and increase of their capacity to accept unexpected changes during labor and feelings of control. The investigators expect this psychological adjustment to lead to a better course of delivery, less interventions including caesarian sections, and subjective birth experience.


Options:
A: Arm Label: Psychoeducative group therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducative group therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Behavioral: Psychoeducative group therapy | Intervention Type: BEHAVIORAL; Name: Psychoeducative group therapy; Assigned to Arm(s): Control, Psychoeducative group therapy
B: Arm Label: Fear of childbirth, music; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Music | Arm Label: Fear of childbirth, control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nulliparous, music; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Music | Arm Label: Nulliparous, control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Music; Assigned to Arm(s): Fear of childbirth, music, Nulliparous, music
C: Arm Label: Study group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): Study group | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Control group
D: Arm Label: Art therapy group; Type: EXPERIMENTAL; Interventions: Other: Art Therapy and therapeutic conversations | Arm Label: Therapeutic conversation group; Type: ACTIVE_COMPARATOR; Interventions: Other: Therapeutic conversations | Intervention Type: OTHER; Name: Art Therapy and therapeutic conversations; Assigned to Arm(s): Art therapy group | Intervention Type: OTHER; Name: Therapeutic conversations; Assigned to Arm(s): Therapeutic conversation group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease
Brief Summary: This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of SC411 in children with sickle cell disease (SCD). The primary objective of the study is to evaluate the safety and tolerability of three different doses of SC411 compared to a placebo. All patients will undergo eight weeks of oral study treatment and a four-week safety follow-up period. Patients will be randomized to one of three dose levels of SC411 or placebo.


Options:
A: Arm Label: L-glutamine; Type: EXPERIMENTAL; Interventions: Drug: L-glutamine | Arm Label: 100% maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: L-glutamine; Assigned to Arm(s): L-glutamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 100% maltodextrin
B: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arginine; Assigned to Arm(s): High Dose, Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Dose Level 1; Type: EXPERIMENTAL; Interventions: Drug: Docosahexaenoic Acid | Arm Label: Dose Level 2; Type: EXPERIMENTAL; Interventions: Drug: Docosahexaenoic Acid | Arm Label: Dose Level 3; Type: EXPERIMENTAL; Interventions: Drug: Docosahexaenoic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Docosahexaenoic Acid; Assigned to Arm(s): Dose Level 1, Dose Level 2, Dose Level 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: LOVAZA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) | Arm Label: Placebo capsule; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA); Assigned to Arm(s): LOVAZA | Intervention Type: OTHER; Name: Placebo Capsules; Assigned to Arm(s): Placebo capsule

Answer: C